Business Wire

ACTILITY

Share
Actility’s ThingPark Powers World’s First LoRA Internet of Things Network

Actility, the industry leader in low power wide area networking, is proud to celebrate the successful deployment of the world’s first nationwide LoRa network for the Internet of Things with Dutch telecom operator KPN. After an intense period of 8 months’ work, several hundred LoRa antennas have been installed all over the Netherlands. KPN’s LoRa project initially went live in the cities of Rotterdam and The Hague. Thanks to strong positive feedback and consumer interest in the early deployments, the network roll-out was accelerated at the beginning of this year, and has just been completed. The KPN network will support uses as varied as street lighting, street signage, waste management and animal tracking.

Actility and KPN have been pioneering the world-leading development of the European Internet of Things together since 2014. Combining Actility’s innovative ThingPark solution for the Internet of Things with KPN’s leading mobile network gives the country a world #1 “best-in-class” solution. It will address the needs of a wide variety of markets with very different requirements, but sharing the common need to connect sensors cost-effectively, over long distances and in both built-up areas and wide open countryside. KPN will leverage the ThingPark Wireless solution to connect a wide range of objects in markets as diverse as agriculture, smart building, transport infrastructure and healthcare applications.

One of the most attractive applications of KPN’s LoRa network is Smart Public Space Management. Citizens across the Netherlands will see a variety of benefits including improved street signage, better waste management in public spaces and smart street lighting.

“We congratulate KPN on being first in the world, thanks to their extremely efficient and successful roll-out across the Netherlands. KPN is a true pioneer and has made good on its ambition to turn the whole country into a smart nation, connecting cities and rural areas, and making life a little smarter for all its inhabitants”, says Actility’s CEO Mike Mulica.

“KPN is pleased with the fruitful collaboration with Actility, which allowed the successful nationwide roll-out in less than a year”, says Jacob Groote, Executive Vice President Service Platforms at KPN.

About Actility

Actility is an innovator and industry leader in LPWA (Low Power Wide Area) large scale infrastructure. Actility’s ThingPark™ is a next generation standards-based IoT platform. The ThingPark Wireless LPWA network provides long-range coverage for low-power consumption sensors. ThingPark Mash-up offers big data storage for sensor data and exposes sensor capabilities through an open API, enabling developers to create vertical applications using the installed base of sensors. The ThingPark platform offers embedded software solutions and cloud solutions to connect devices with innovative applications. With its dedicated online marketplace for IoT sensors, applications and network solutions, ThingPark simplifies and accelerates the roll-out of innovative IoT services. Actility is a founding member of the LoRa Alliance: the largest, most powerful open standards-based enabler of the Internet of Things. To find out more, visit www.thingpark.com .

About KPN: to learn more visit www.kpn.com

Contact:

Actility
Anne van Gemert
anne.vangemert@actility.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye